EGFR and neoplasm: We tested for the binding and detection of three frequently used clinically approved monoclonal antibodies in tumor cell lines positive for the respective target: PT1590 cells were treated with trastuzumab targeting the HER2 receptor, Ramos cells with rituximab targeting CD20 and UTSCC2 cells with cetuximab recognizing the EGFR (Fig. 6).